arrow
Back
K

K.N. Chi

University of British Columbia

20H-index
175Paper Count
2.4KCitation Count
Published Papers 51
Publication Date
A Comprehensive Analysis of HER2 status Heterogeneity Using Matched Samples Among Potential Beneficiaries of Trastuzumab Deruxtecan Therapy In Non-Small Cell Lung Cancer
err2025-11-21
err0
PREAI
errHaiyue Wang; Wei Sun; Chenglong Wang; Xin Yang; Kaiwen Chi; Xinying Liu; Xiaozheng Huang; Lixin Zhou; Dongmei Lin
errShare
errSave
A retrospective cross-sectional study of FGFR2b alterations in Chinese patients with advanced squamous non-small cell lung cancer: prevalence, programmed death-ligand 1 co-expression patterns, and association with clinical outcomes
err2025-10-31
err0
PREAI
errWang, Xiyuan; Chi, Kaiwen; Wang, Haiyue; Sun, Shuguang; Ao, Chunxia; Li, Jiongyan; Ge, Yuanjie; Yang, Chen; Fu, Yayuan; Lin, Dongmei; Tang, Renhong; Sun, Wei
errShare
errSave
Niclosamide suppresses gastric cancer progression through YTHDF2 inhibition-affected lactate metabolic reprogramming
err2025-10-27
err0
errOAAI
errMosheng Tang; Yiyin Hu; Xiaohui Zhu; Jichen Dai; Rui Li; Xinran Feng; Kangrui Chi; Xinyi Li; Qiaofei Zhang; Ke Chen; Ruoying Cao; Hanqing Zhu; Haoran Huang; Haipeng Wu; Lejia Sun; Tongke Chen; Jun Wu; Huafu Wang; Zhihong Gui
errShare
errSave
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer
err2025-10-27
err0
errOAAI
errT. Virtanen; E.M. Kwan; K. Parekh; J.V.W. Bacon; C.F. Huang; I.P.L. Yu; L. Ryyppö; C. Bernales; G. Donnellan; C. Tam; J. Sipola; J. Nikkola; G. Vandekerkhove; S.H. Tolmeijer; K. Kukkonen; null Adelia; B.J. Eigl; D. Finch; R. Gagnon; Y. Takieldeen; E. Hardy; D. Khalaf; C. Kollmannsberger; J.-M. Lavoie; C. Maurice-Dror; S. Miller; L. Nappi; K. Noonan; S. Parimi; A. Riminchan; E. Sartori-Mueller; M. Soleimani; J. Vergidis; M. Zulfiqar; A. Hansen; S. Hotte; M. Jafri; M. Kolinsky; S.D. Mukherjee; M. Ong; A.A.N. Rose; W. Tu; E. Winquist; A.M. Bergman; K. van der Zande; W. Zwart; N. Mehra; N.P. van Erp; J.L. Zhao; D. Rathkopf; C. Barbieri; D. Quigley; M. Nykter; N.A. Lack; K.N. Chi; M. Annala; A.W. Wyatt
errShare
errSave
Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
err2025-07-17
err0
errOAAI
errK. Fizazi; K.N. Chi; N.D. Shore; K. Herrmann; J.S. de Bono; D. Castellano; J.M. Piulats; A. Fléchon; X.X. Wei; H. Mahammedi; G. Roubaud; M. Fleming; T. Haas; S. Ghebremariam; T.N. Kreisl; S. Rajagopalan; O. Sartor; M.J. Morris
errShare
errSave
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)
err2025-05-20
err0
PREAI
errH.-M. Lin; T. Scheinberg; N. Portman; R.M.N. Kim; R. Mellor; K. Huynh; A.N. Faulkner; N.A. Mellett; I.D. Davis; A. Martin; D. Sullivan; A. Joshua; M. McJannett; V. Subhash; S. Yip; A.A. Azad; I.C. Marschner; S.A. North; R.S. McDermott; K.N. Chi; M.R. Stockler; C.J. Sweeney; P.J. Meikle; L.G. Horvath
errShare
errSave
Oral anticoagulants or antiplatelets for cryptogenic stroke: a systematic review and meta-analysis
err2024-10-28
err0
PREAI
errChi, K.; Song, J.; El Zarif, T.; Chiang, C. C.; Lee, P. L.; Chang, Y. C.; Nanna, M.; Nanna, M. G.
errShare
errSave
Does the primary location and metastatic timing of colorectal cancer influence the survival of patients with brain metastasis? A meta-analysis
err2024-09-01
err0
PREAI
errSong, J.; Yim, C.; Tsai, T-C.; Memon, R.; Chi, K-Y.; Gong, C.; Lin, B-W.; Lin, H-M.; Chang, Y.
errShare
errSave
errShare
errSave
Niraparib plus abiraterone acetate plus prednisone (NIRA plus AAP) as first-line treatment in patients with BRCA plus metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study
err2023-11-01
err0
PREAI
errSaad, M.; Chi, K. N.; Sandhu, S. K.; Attard, G.; Ye, D.; Li, L.; Jung, W.; Pang, S-T.; Francis, P. S. J.; Li, S.; Dibaj, S.; Zhang, J.; Kim, W.; Lopez-Gitlitz, A.; Wu, D.; Singh, A.; De Vries, R.; Zhang, L.; Lee, J. Y.
errShare
errSave
Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castrationsensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT)
err2023-10-01
err4
PREAI
errMerseburger, A. S.; Agarwal, N.; Bjartell, A.; Uemura, H.; Juarez, A.; Bhaumik, A.; Boehm, J.; Tran, N.; Krochmann, N.; Nematian, M.; Mundle, S. D.; Brookman-May, S. D.; Mccarthy, S. A.; Chi, K. N. N.; Chowdhury, S.
errShare
errSave
Prognostic value of neutrophil-to-lymphocyte ratio and lymphopenia in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [177Lu]Lu-PSMA-617: VISION post hoc analysis
err2023-10-01
err0
errOAAI
errWei, X. X.; Chi, K. N. N.; de Bono, J. S.; Fizazi, K.; Krause, B.; Herrmann, K.; Rahbar, K.; Tagawa, S. T.; Morris, M. J.; Meisel, A.; Holder, G.; Mirante, O.; Wu, J.; Sartor, O.
errShare
errSave
Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
err2023-10-01
err0
errOAAI
errHorvath, L. G.; Davis, I. D.; Martin, A.; Zielinski, R.; Thomson, A.; Tan, T. H.; Sandhu, S. K.; Reaume, M. N.; Pook, D.; Parnis, F.; North, S.; Marx, G. M.; McCaffrey, J. A.; McDermott, R. S.; Lawrence, N.; Frydenberg, M.; Chowdhury, S.; Chi, K. N. N.; Stockler, M. R.; Sweeney, C.
errShare
errSave
Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA plus AAP) in homologous recombination repair gene-altered (HRR plus ) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial
err2023-10-01
err1
errOAAI
errAttard, G.; Sandhu, S. K.; Rathkopf, D.; Castro, E.; Saad, M.; Smith, M. R.; Small, E. J. J.; Olmos, D.; Gomes, A. J. P. D. S.; Roubaud, G.; Zurawski, B.; Efstathiou, E.; Wu, D.; Diorio, B.; Urtishak, K.; Singh, U.; Xu, Y.; Lopez-Gitlitz, A.; del Corral, A.; Chi, K. N. N.
errShare
errSave
Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
err2023-10-01
err0
PREAI
errMorris, M. J.; Armstrong, A. J.; Chi, K. N. N.; de Bono, J. S.; Herrmann, K.; Krause, B.; Rahbar, K.; Sartor, O.; Tagawa, S. T.; Nagarajah, J.; Wei, X. X.; Nordquist, L. T.; Koshkin, V. S.; Saad, F.; Vickers, A.; Ghouse, R.; Wu, J.; Mirante, O.; Fizazi, K.
errShare
errSave
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
err2023-09-01
err68
errOAAI
errChi, K. N.; Sandhu, S.; Smith, M. R.; Attard, G.; Saad, M.; Olmos, D.; Castro, E.; Roubaud, G.; Gomes, A. J. Pereira de Santana; Small, E. J.; Rathkopf, D. E.; Gurney, H.; Jung, W.; Mason, G. E.; Dibaj, S.; Wu, D.; Diorio, B.; Urtishak, K.; del Corral, A.; Francis, P.; Kim, W.; Efstathiou, E.
errShare
errSave
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
err2023-05-01
err34
errOAAI
errChowdhury, S.; Bjartell, A.; Agarwal, N.; Chung, B. H.; Given, R. W.; Gomes, A. J. Pereira de Santana; Merseburger, A. S.; Ozguroglu, M.; Soto, A. Juarez; Uemura, H.; Ye, D.; Brookman-May, S. D.; Londhe, A.; Bhaumik, A.; Mundle, S. D.; Larsen, J. S.; McCarthy, S. A.; Chi, K. N.
errShare
errSave
Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
err2021-09-01
err6
errOAAI
errFizazi, K.; Herrmann, K.; Krause, B. J.; Rahbar, K.; Chi, K. N.; Morris, M. J.; Sartor, O.; Tagawa, S. T.; Kendi, A. T.; Vogelzang, N. J.; Calais, J.; Nagarajah, J.; Wei, X. X.; Koshkin, V. S.; Beauregard, J-M.; Chang, B.; DeSilvio, M.; Messmann, R. A.; de Bono, J.
errShare
errSave
Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)
err2021-09-01
err2
errOAAI
errSmith, M. R.; Sandhu, S. K.; George, D. J.; Chi, K. N.; Saad, F.; Thiery-Vuillemin, A.; Stahl, O.; Olmos, D.; Danila, D.; Gafanov, R.; Castro, E.; Moon, H.; Joshua, A. M.; Mason, G. E.; Espina, B. M.; Liu, Y.; Bevans, K. B.; Lopez-Gitlitz, A.; Francis, P.; Fizazi, K.
errShare
errSave
Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)
err2021-09-01
err1
errOAAI
errSternberg, C. N.; Bracarda, S.; de Bono, J. S.; Sweeney, C.; Chi, K. N.; Olmos, D.; Sandhu, S. K.; Massard, C.; Garcia, J.; Schenkel, F.; Chen, G.; Harris, A.; Hinton, H.; Matsubara, N.
errShare
errSave